

CDPH ASP Toolkit 2015

Example 2.1 Palomar Health ASP Subcommittee (1 of 2)

Reviewed for annual review. No changes needed.

| | | | |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------|
|  | Antibiotic Sub-Committee | | Procedure |
| | 37812 | | In preparation (Rev: 3) |
| Source: Clinical Pharmacy | Applies to Facilities: Palomar Medical Center Downtown Palomar Medical Center West Pomerado Hospital Escondido Surgery Center | Applies to Departments: Pharmacy All Clinical Departments | |

- I. **PURPOSE:**
 - A. To define the role of the Antibiotic Sub-Committee.
- II. **DEFINITIONS:**
 - A. n/a
- III. **STANDARDS OF PRACTICE:**
 - A. Performed by: n/a
 - B. The Antibiotic Sub-Committee is a medical staff committee that reports to the Pharmacy and Therapeutics & Nutrition Committee (P & T) which in turn reports to the Quality Management Committee. This is a combined Palomar Health Committee.
 - C. The Antibiotic Sub-Committee monitors antimicrobial usage and sets standards to encourage the judicious use of antimicrobials.
 - D. The Antibiotic Sub-Committee makes recommendations to the Pharmacy & Therapeutics Committee concerning the hospitals' antimicrobial and vaccine formulary. The committee will review, revise, and recommend the antimicrobial formulary as may be required.
 - E. The chair of the committee is an Infectious Disease specialist. The committee is comprised of the Infectious Disease clinical pharmacist, a microbiologist, infection preventionists, and representatives from a cross section of medical specialties in the hospital.
 - F. The membership of the Antibiotic Sub-Committee is appointed by department heads. New members are appointed as members leave or accept other duties. The committee will review antimicrobial usage within each hospital through ongoing monitoring and audits as may be required.
 - G. The Antibiotic Sub-Committee will review reports of antimicrobial adverse reactions in both institutions.
 - H. The Antibiotic Sub-Committee will develop guidelines for use for all new antimicrobials added to the formulary.
 - I. The Antibiotic Sub-Committee will review and approve all order sets which contain antimicrobials.
- IV. **STEPS OF PROCEDURE**
 - A. Equipment: n/a
- V. **PUBLICATION HISTORY:**

| Revision Number | Effective Date | Document Owner at Publication | Version Notes |
|------------------|----------------|------------------------------------------|---------------------------------------------------|
| 3 (this version) | | Olga DeTorres, Clinical Pharm Specialist | Change PPH to Palomar Health throughout document. |
| 2 (Changes) | 03/08/2012 | Olga DeTorres, Clinical Pharm Specialist | P&T approved in 1/12 QMC approved in 2/12 |

For more info about this example contact Olga DeTorres, PharmD at Olga.DeTorres@palomarhealth.org

CDPH ASP Toolkit 2015

Example 2.1 Palomar Health ASP Subcommittee (continued 2 of 2)

Reviewed for annual review. No changes needed.

| | | | |
|----------------|------------|------------------------------------------|-----------------------------------------------------------------------------------|
| | | | Antibiotic Committee approved in 1/12 Formatted by ms |
| 1 (Changes) | 01/05/2012 | Olga DeTorres, Clinical Pharm Specialist | Modified procedure to define committee's role in relation to the P & T Committee. |
| 0 (Changes) | 11/30/2010 | Olga DeTorres, Clinical Pharm Specialist | New procedure to define the responsibilities of the Antibiotic Sub-Committee. |

VI.

Authorized Signer(s): (unsigned) Jeremy Lee, PharmD, BCPS, Manager Clinical Pharmacy Services
(unsigned) Cedric Terrell, Director Pharmacy Services
(unsigned) Cttee: Medical Executive, PMC
(unsigned) Cttee: Medical Executive, Pom
(unsigned) David A Tam, MD, FACHE, Chief Administrative Officer, POM

VI. **REFERENCES:**

| Reference Type | Title | Notes |
|----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | <i>Paper copies of this document may not be current and should not be relied on for official purposes. The current version is in Lucidoc at . https://www.lucidoc.com/cgi/doc-gw.pl?ref=pphealth:37812\$3</i> |

For more info about this example contact Olga DeTorres, PharmD at Olga.DeTorres@palomarhealth.org

CDPH does not endorse the specific content or recommendations included in these examples. They are for illustrative purposes only.